Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: A magnetic resonance imaging study

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Hoenig, Michel R ^a   Cowin, Gary ^a   Buckley, Raymond ^a   McHenery, Christine ^a   Coulthard, Allan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTANOL; DESMOSTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL; C REACTIVE PROTEIN; CHOLESTEROL; INSULIN; LIPID;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAABDOMINAL FAT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ABDOMINAL FAT; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; PROTHROMBIN TIME;

ABDOMINAL FAT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; PROTHROMBIN TIME;

EID: 78651507377     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-12     Document Type: Article

References (34)

1. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. WY Fujimoto RW Bergstrom EJ Boyko KW Chen DL Leonetti L Newell-Morris JB Shofer PW Wahl, Diab Care 1999 22 11 1808 1812 10.2337/diacare.22.11.1808 (Pubitemid 29521866)
2. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. S Yusuf S Hawken S Ounpuu L Bautista MG Franzosi P Commerford CC Lang Z Rumboldt CL Onen L Lisheng,, et al. Lancet 2005 366 9497 1640 1649 10.1016/S0140-6736(05)67663-5 16271645
3. The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat. DJ Nieves M Cnop B Retzlaff CE Walden JD Brunzell RH Knopp SE Kahn, Diabetes 2003 52 1 172 179 10.2337/diabetes.52.1.172 12502509
4. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. CS Fox JM Massaro U Hoffmann KM Pou P Maurovich-Horvat CY Liu RS Vasan JM Murabito JB Meigs LA Cupples,, et al. Circulation 2007 116 1 39 48 10.1161/CIRCULATIONAHA. 106.675355 17576866 (Pubitemid 47016245)
5. Contribution of visceral fat accumulation to the risk factors for atherosclerosis in non-obese Japanese. T Miyawaki M Abe K Yahata N Kajiyama H Katsuma N Saito, Intern Med 2004 43 12 1138 1144 10.2169/internalmedicine.43. 1138 15645647
6. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. MR Hoenig, Vasc Health Risk Manag 2008 4 1 143 156 10.2147/vhrm.2008.04.01.143 18629364
7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, Circulation 2004 110 2 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
8. Non-High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Y Cui RS Blumenthal JA Flaws MK Whiteman P Langenberg PS Bachorik TL Bush, Arch Intern Med 2001 161 11 1413 1419 10.1001/archinte.161.11.1413 11386890
9. Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes. J Liu C Sempos RP Donahue J Dorn M Trevisan SM Grundy, Diabetes Care 2005 28 8 1916 1921 10.2337/diacare.28.8.1916 16043732
10. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. A Sachdeva CP Cannon PC Deedwania KA Labresh SC Smith Jr D Dai A Hernandez GC Fonarow, Am Heart J 2009 157 1 111 117 e112. 10.1016/j.ahj.2008.08.010 19081406
11. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. J Liu CT Sempos RP Donahue J Dorn M Trevisan SM Grundy, Am J Cardiol 2006 98 10 1363 1368 10.1016/j.amjcard.2006.06.032 17134630
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. ATPIII, Circulation 2002 106 25 3143 3421 12485966
13. SERUM PLANT STEROLS AND CHOLESTEROL PRECURSORS REFLECT CHOLESTEROL ABSORPTION AND SYNTHESIS IN VOLUNTEERS OF A RANDOMLY SELECTED MALE POPULATION. TA MIETTINEN RS TILVIS YA KESANIEMI, Am J Epidemiol 1990 131 1 20 31 2293749
14. Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. TA Miettinen RS Tilvis YA Kesaniemi, Metabolism 1989 38 2 136 140 10.1016/0026-0495(89)90252-7 2913464
15. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. R Muniyappa S Lee H Chen MJ Quon, Am J Physiol Endocrinol Metab 2008 294 1 15 26 10.1152/ajpendo.00645. 2007 17957034
16. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. PA Sarafidis AN Lasaridis PM Nilsson MI Pikilidou PC Stafilas A Kanaki K Kazakos J Yovos GL Bakris, J Hum Hypertens 2007 21 9 709 716 10.1038/sj.jhh.1002201 17443211
17. A multicompartment body composition technique based on computerized tomography. B Chowdhury L Sjostrom M Alpsten J Kostanty H Kvist R Lofgren, Int J Obes Relat Metab Disord 1994 18 4 219 234 8044196
18. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. MR Hoenig KM Kostner SJ Read PJ Walker JJ Atherton, Endocr Metab Immune Disord Drug Targets 2007 7 3 153 166 10.2174/187153007781662567 17897042
19. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients. AL Vlek Y van der Graaf W Spiering FL Visseren, J Hum Hypertens 2008 22 5 358 365 10.1038/jhh.2008.5 18273039
20. Metabolic syndrome and vascular risk in patients with peripheral arterial occlusive disease. AL Vlek Y van der Graaf MA Sluman FL Moll FL Visseren SS Group, J Vasc Surg 2009 50 1 61 69 10.1016/j.jvs.2008.12.070 19223144
21. Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. AM Wassink Y Van Der Graaf SS Soedamah-Muthu W Spiering F Visseren G Smart Study, Diab Vasc Dis Res 2008 5 2 114 122 10.3132/dvdr.2008.019 18537099
22. Brevetti G, Laurenzano E, Giugliano G, Lanero S, Brevetti L, Luciano R, Chiariello M, 2010, Nutrition, Metabolism and Cardiovascular Diseases, 20(9), 676-682
23. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. A Onat GS Avci MM Barlan H Uyarel B Uzunlar V Sansoy, Int J Obes Relat Metab Disord 2004 28 8 1018 1025 10.1038/sj.ijo.0802695 15197408
24. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. MA Denke CT Sempos SM Grundy, Arch Intern Med 1993 153 9 1093 1103 10.1001/archinte.153.9.1093 8481076
25. Characteristics associated with apoprotein and lipoprotein lipid levels in middle-aged women. EN Meilahn LH Kuller EA Stein AW Caggiula KA Matthews, Arteriosclerosis 1988 8 5 515 520 3142451
26. Obesity and serum lipids: an evaluation of the relative contribution of body fat and fat distribution to lipid levels. CJ Foster RL Weinsier R Birch DJ Norris RS Bernstein J Wang RN Pierson TB Van Itallie, Int J Obes 1987 11 2 151 161 3610468
27. Relationships of low density lipoprotein cholesterol with age and other factors: a cross-sectional analysis of the CARDIA study. DR Jacobs Jr GL Burke K Liu G Cutter G Hughes S Hulley S Sidney, Ann Clin Res 1988 20 1-2 32 38 3261566
28. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. MA Denke CT Sempos SM Grundy, Arch Intern Med 1994 154 4 401 410 10.1001/archinte.154.4.401 8117172
29. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. AD Sniderman CD Furberg A Keech JE Roeters van Lennep J Frohlich I Jungner G Walldius, Lancet 2003 361 9359 777 780 10.1016/S0140- 6736(03)12663-3 12620753
30. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. G Walldius I Jungner I Holme AH Aastveit W Kolar E Steiner, The Lancet 2001 358 9298 2026 2033 10.1016/S0140-6736(01)07098-2 (Pubitemid 34084825)
31. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. AC St-Pierre B Cantin GR Dagenais JP Despres B Lamarche, Am J Cardiol 2006 97 7 997 1001 10.1016/j.amjcard.2005.10. 060 16563904
32. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. CM Ballantyne TC Andrews JA Hsia JH Kramer C Shear, Am J Cardiol 2001 88 3 265 269 10.1016/S0002-9149(01)01638-1 11472705
33. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. PJ Barter CM Ballantyne R Carmena M Castro Cabezas MJ Chapman P Couture J de Graaf PN Durrington O Faergeman J Frohlich,, et al. J Intern Med 2006 259 3 247 258 10.1111/j.1365-2796.2006.01616.x 16476102
34. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. AD Sniderman AC St-Pierre B Cantin GR Dagenais JP Despres B Lamarche, Am J Cardiol 2003 91 10 1173 1177 10.1016/S0002-9149(03)00262-5 12745098